Draft Medical Policies
BlueCross BlueShield of Tennessee

BlueCross BlueShield of Tennessee works to ensure that Medical Policies are developed in an open, collaborative manner with our providers. We invite you to submit comments during the development phase of our Medical Policies.

Medical policies are developed using an evidence-based evaluation process. The medical evidence used in this process comes from several sources, including independent medical technology review organizations, the peer reviewed medical literature, and expert opinions from BCBST network specialists. We especially welcome comments that include this type of information. All Medical Policies are reviewed and approved by a panel of BCBST Medical Directors as well as board certified network physicians before final adoption by the company.

Policy Policy Name Date Posted Date Removed
ID_CHS_17052026_1126 Bendamustine Products (Treanda®, Belrapzo®, Bendeka®, Vivimusta™, Bendamustine) 10/02/26 11/10/26
ID_CHS_60222026_1126 Glofitamab-gxbm (Columvi™) 10/02/26 11/10/26
ID_CHS_16752026_1126 Avelumab (Bavencio®) 10/02/26 11/10/26
ID_CHS_23852026_1126 Axicabtagene Ciloleucel (Yescarta®) 10/02/26 11/10/26
ID_CHS_64762026_1126 Nogapendekin alfa inbakicept-pmln (Anktiva ®) 10/02/26 11/10/26
ID_CHS_26592026_1126 Patisiran Lipid Complex (Onpattro®) 10/02/26 11/10/26
ID_CHS_17022026_1126 Pralatrexate (Folotyn®); Pralatrexate 10/02/26 11/10/26
ID_CHS_60402026_1126 Rozanolixizumab‐noli (Rystiggo®) 10/02/26 11/10/26
ID_CHS_22942026_1126 Tisagenlecleucel (Kymriah®) 10/02/26 11/10/26
ID_CHS_73182026_1126 Onasemnogene Abeparvovec-brve (Itvisma ®) 10/02/26 11/10/26
ID_CHS_17002025_1126 Brentuximab Vedotin (Adcetris®) 10/02/26 11/10/26
ID_CHS_66652026a_1126 Atezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza™) 10/02/26 11/10/26
ID_CHS_71972026b_1126 Pembrolizumab and Berahyaluronidase alfa-pmph (Keytruda Qlex™) 10/02/26 11/10/26
ID_CHS_69842026a_1126 Nipocalimab-aahu (Imaavy™) 10/15/26 11/10/26
ID_CHS_39682026a_1126 Inebilizumab-cdon (Uplizna™) 10/02/26 11/10/26
ID_CHS_28352026_1126 Ravulizumab-cwvz (Ultomiris®) 10/08/26 11/10/26
ID_CHS_30952026_1126 Polatuzumab Vedotin-piiq (Polivy®) 10/08/26 11/10/26
ID_CHS_57112026_1126 Nadofaragene firadenovec-vncg (Adstiladrin®) 10/08/26 11/10/26
ID_CHS_71362026_1126 Multiple Sclerosis Products:(Ocrelizumab [Ocrevus™], Ocrelizumab and Hyaluronidase-ocsq [Ocrevus Zunovo™], Ublituximab-xiiy [Briumvi™]) 10/08/26 11/10/26
ID_CHS_70372026_1126 Mitomycin (Zusduri™) 10/08/26 11/10/26
ID_CHS_45132026_1126 Lisocabtagene Maraleucel (Breyanzi®) 10/08/26 11/10/26
ID_CHS_57322026a_1126 Lecanemab-irmb (Leqembi™) 10/08/26 11/10/26
ID_CHS_72292026_1126 Gemcitabine (Inlexzo™) 10/08/26 11/10/26
ID_CHS_65582026_1126 Donanemab-azbt (KISUNLA™) 10/08/26 11/10/26
ID_CHS_60322026_1126 Delandistrogene moxeparvovec-rokl (Elevidys®) 10/08/26 11/10/26
ID_CHS_30432026_1126 Collagenase Clostridium Histolyticum (Xiaflex®) 10/08/26 11/10/26
ID_CHS_17662026a_1126 Atezolizumab (Tecentriq®) 10/08/26 11/10/26
ID_CHS_20992026_1126 Rituximab and Hyaluronidase Human (Rituxan Hycela®) 10/08/26 11/10/26
ID_CHS_20812026_1126 Temsirolimus (Torisel®) 10/08/26 11/10/26
ID_CHS_54912026_1126 Vutrisiran (Amvuttra™) 10/08/26 11/10/26
ID_BT_35112026_1126 Teprotumumab-trbw (Tepezza®) 10/08/26 11/10/26
DMP1026-01 Artificial Intervertebral Disc 10/15/26 11/15/26

 

Pharmacy Policy Comments:

Please reference the policy name or tracking number in your comments.
To submit comments about the draft Pharmacy Policies:
Click the “Pharmacy Policy Comments” above or click here: Comments or Feedback.

Medical Policy Comments:

Please reference the policy name or tracking number in your comments.
To submit comments about the draft Medical Policies:
Click the “Medical Policy Comments” above or click here: Comments or Feedback.

Comments can also be mailed to:

BlueCross BlueShield of Tennessee
Medical Policy
1 Cameron Hill Circle
Chattanooga, TN 37402